A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan
← catalyst calendarNCT06864585 · readout in 953 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
59actual
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-20 | actual | When the study began enrolling |
| Primary completion | 2029-03-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Infectious Diseases
Intervention
- Drug: Avibactam sodium/Ceftazidime hydrate — also filed as Zavicefta
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with adverse drug reactions (ADRs)
measured From the start date of the administration to 28 days after the administration (or 14 days after the date of discontinuation if the administration is discontinued)
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed